Researchers develop potential treatment for fatal, incurable kidney disease

Dallas: Researchers at UT Southwestern Medical Center, working with a California biotech firm, have developed a potential drug to treat polycystic kidney disease – an incurable genetic disease that often leads to end-stage kidney failure. The drug, now called RGLS4326, is in preclinical animal testing at San Diego-based Regulus Therapeutics Inc. An investigational new drug filing to pave the way for human clinical trials is expected later this year, said Dr. Vishal Patel, Assistant Professor of Internal Medicine at UT Southwestern.

Low-potassium diet increases risk of losing donor kidney

Groningen: Patients who eat a low-potassium diet after a kidney transplantation have a higher risk of losing function of the donated kidney and dying prematurely. These are the conclusions of researchers from the department of Nephrology/Internal Medicine at the UMCG. The results of their research are today published in The American Journal of Clinical Nutrition.

Close Monitoring of Renal Tumors May Provide Alternative to Surgery

Mount Sinai. US: In patients with small renal tumors confined to the kidneys, close, active monitoring, as opposed to immediate surgery, is associated with low rates of tumor growth or death, according to a study by a researcher at the Icahn School of Medicine at Mount Sinai published in the September issue of the Journal of Urology.

Membranous glomerulonephritis

Source: Food and Drug Administration. May 2014
Membranous glomerulonephritis (MGN) is a specific type of kidney disease, due to the body’s rejection of its own kidney tissue (autoimmune) or due to another cause (such as an infection).